Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor

European Journal of Preventive Cardiology

Volumn 24, Issue 3, 2017, Pages 52-60

  Norhammar, Anna ^a,b   Mellbin, Linda ^a   Cosentino, Francesco ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ST GÖRAN S HOSPITAL   (Sweden)

Author keywords

Abnormal glucose tolerance; Acute coronary syndrome; Cardiovascular safety; Diabetes; Glucose control; Glucose lowering drugs; Myocardial infarction; Secondary prevention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; EPTIFIBATIDE; FONDAPARINUX; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; POTASSIUM; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TROPONIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; FIBRINOLYTIC AGENT;

ABNORMAL BLOOD PRESSURE; ACUTE CORONARY SYNDROME; ALL CAUSE MORTALITY; ARTICLE; BLEEDING; CALORIC INTAKE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL OUTCOME; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DUAL ANTIPLATELET THERAPY; GLUCOSE INFUSION; GLYCEMIC CONTROL; GRAFT OCCLUSION; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITAL MORTALITY; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MALNUTRITION; METABOLIC REGULATION; MORBIDITY; MORTALITY RATE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANCE TRAINING; RISK FACTOR; SECONDARY PREVENTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME; BLOOD; CARDIOVASCULAR DISEASE; DISEASE EXACERBATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MORTALITY; PROCEDURES; RECURRENT DISEASE; RISK REDUCTION;

ANTICOAGULANTS; BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DISEASE PROGRESSION; FIBRINOLYTIC AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL REVASCULARIZATION; PREVALENCE; RECURRENCE; RISK FACTORS; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 85042767930     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487317709554     Document Type: Article

References (39)

1. International Diabetes Federation. IDF Diabetes Atlas, 7th edition. Available at: www.diabetesatlas.org (2016).
2. Lind M, Garcia-Rodriguez LA, Booth GL, et al. Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: A population-based study. Diabetologia 2013; 56: 2601–2608.
3. Norhammar A, Lindbäck J, Rydén L, et al. Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: A time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart 2007; 93: 1577–1583.
4. Dotevall A, Hasdai D, Wallentin L, et al. Diabetes mellitus: Clinical presentation and outcome in men and women with acute coronary syndromes. Data from the Euro Heart Survey ACS. Diabet Med 2005; 22: 1542–1550.
5. Arnold SV, Lipska KJ, Li Y, et al. Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. Am Heart J 2014; 168(4): 466–470.
6. Opie LH and Stubb WA. Carbohydrate metabolism in cardiovascular disease. Clin Endocrinol Metab 1976; 3: 703–729.
7. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study. Lancet 2002; 359(9324): 2140–2144.
8. Wallander M, Malmberg K, Norhammar A, et al. Oral glucose tolerance test: A reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice: A report on repeated oral glucose tolerance tests from the GAMI study. Diabetes Care 2008; 31(1): 36–38.
9. Bartnik M, Rydén L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25(21): 1880–1890.
10. Gyberg V, De Bacquer D, Kotseva K, et al. Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: A report from EUROASPIRE IV – A survey from the European Society of Cardiology. Eur Heart J 2015; 36(19): 1171–1177.
11. Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34(39): 3035–3087.
12. Kannel WB and McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979; 241: 2035–2039.
13. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case–control study. Lancet 2004; 364(9438): 937–952.
14. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1.9 million people. Lancet Diabetes Endocrinol 2015; 3: 105–113.
15. Norhammar A, Bodegård J, Nyström T, et al. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: A nationwide study in Sweden, 2006–2013. Diabetologia 2016; 59: 1692–1701.
16. Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med 2013; 368: 1613–1624.
17. US Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Division of Health Care Statistics. Crude and age-adjusted hospital discharge rates for major cardiovascular disease as first-listed diagnosis per 1,000 diabetic population, United States, 1988–2006. Available at: http://www.cdc.gov/dia-betes/statistics/cvdhosp/cvd/fig3.htm (2014, accessed 27 August 2015).
18. Gaede P, Lund-Andersen H, Parving H-H, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–591.
19. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357(9261): 995–1001.
20. Johansson I, Dahlström U, Edner M, et al. Prognostic implications of diabetes in ischemic and non-ischemic heart failure in the Swedish Heart Failure Registry. J Am Coll Cardiol 2016; 68: 1404–1416.
21. Piepoli MF, Hoes AW, Agewell S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315–2381.
22. American Diabetes Association. Standards of medical care in diabetes – 2017. Diabetes Care 2017; 40: S1–S2.
23. Ritsinger V, Saleh N, Lagerqvist B, et al. High event rate after a first percutaneous coronary intervention (PCI) in patients with diabetes. Results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Circ Cardiovasc Interv 2015; 8(6): e002328.
24. Ritsinger V, Tanoglidi E, Malmberg K, et al. Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: Long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. Diab Vasc Dis Res 2015; 12: 23–32.
25. George A, Bhatia RT, Buchanan GL, et al. Impaired glucose tolerance or newly diagnosed diabetes mellitus diagnosed during admission adversely affects prognosis after myocardial infarction: an observational study. PLoS One 2015; 10(11): e0142045.
26. Malmberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction – Long-term results from the Diabetes and Insulin–Glucose Infusion in Acute Myocardial Infarction. Circulation 1999; 99: 2626–2632.
27. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur Heart J 2005; 26: 650–661.
28. Opie LH. Metabolic management of acute myocardial infarction comes to the fore and extends beyond control of hyperglycemia. Circulation 2008; 117: 2172–2177.
29. Kloner RA and Nesto RW. Glucose–insulin–potassium for acute myocardial infarction: Continuing controversy over cardioprotection. Circulation 2008; 117: 2523–2533.
30. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009; 119: 351–357.
31. Goto A, Arah OA, Goto M, et al. Severe hypoglycaemia and cardiovascular disease: Systematic review and metaanalysis with bias analysis. BMJ 2013; 347: 4533.
32. Beckman JA, Paneni F, Cosentino F, et al. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part II. Eur Heart J 2013; 34: 2444–2452.
33. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860.
34. Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(3): 267–315.
35. Szummer K, Oldgren J, Lindhagen L, et al. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. JAMA 2015; 313: 707–716.
36. Kolh P, Windecker C, Alfonso F, et al. ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2014; 46: 517–592.
37. Stenestrand U, James SK, Lindbäck J, et al. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: Long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2010; 31(2): 177–186.
38. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360(10): 961–972.
39. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367: 2375–2384.